Overexpression of Gremlin promotes non-small cell lung cancer progression

Yunhong Yin1, Yie Yang2, Liyun Yang3

  • 1Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, 250012, China.

Insights

Gremlin protein promotes non-small cell lung cancer (NSCLC) growth and resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Silencing Gremlin may restore sensitivity to gefitinib in NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Gremlin, a bone morphogenetic protein (BMP) antagonist, is implicated in various cancers, but its role in NSCLC and resistance to EGFR-TKIs is not well understood.

Purpose of the Study:

  • To investigate the role of Gremlin in NSCLC development and its association with resistance to EGFR-TKIs.
  • To evaluate Gremlin as a potential therapeutic target for enhancing EGFR-TKI sensitivity in NSCLC.

Main Methods:

  • Quantitative real-time PCR and western blot were used to measure Gremlin mRNA and protein expression in NSCLC tissues and cell lines.
  • Gremlin function was assessed using interference RNA (siRNA) in NSCLC cells.
  • Proliferation and apoptosis assays were performed on gefitinib-resistant PC-9/GR cells with and without Gremlin knockdown.

Main Results:

  • Gremlin expression was significantly higher in NSCLC tissues compared to normal lung tissues.
  • Gremlin was overexpressed in gefitinib-resistant PC-9/GR cells relative to sensitive PC-9 cells.
  • Gremlin knockdown in PC-9/GR cells reduced cell proliferation, increased BMP7 protein expression, and enhanced gefitinib-induced apoptosis.

Conclusions:

  • Gremlin contributes to gefitinib resistance in NSCLC.
  • Targeting Gremlin may represent a therapeutic strategy to overcome EGFR-TKI resistance in NSCLC patients.